An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
Due to the COVID-19 pandemic, the global Orally Disintegrating Tablets market size is estimated to be worth US$ 13890 million in 2021 and is forecast to a readjusted size of US$ 30030 million by 2028 with a CAGR of 11.5% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Orally Disintegrating Tablets market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Orally Disintegrating Tablets landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The classification of Orally Disintegrating Tablet includes Anti-Psychotics Drug, Anti-Epileptics Drug and others, and the proportion of Anti-Psychotics Drug in 2017 is about 16.6%, Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20.3% revenue share of the global market by 2025 end. With a noteworthy 15.7% CAGR, this segment will retain its supremacy over other drug class segments during the eight-year period.
This report focuses on Orally Disintegrating Tablets volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Orally Disintegrating Tablets market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Orally Disintegrating Tablets Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer